Tarsus Pharmaceuticals, Inc. Common Stock (TARS) Stock Price
TARSStock
$71.76+23.38%52W
Market Cap$3.15B
P/E—
PEG Ratio—
Div yield—
Beta0.45
TARS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-16.26%
Price vs S&P 500 (4W)15.48%
VGM Score60.21
TARS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.20 | -$0.43 | -119.39%(-$0.23) | |
| Q1 2026 | -$0.42 | -$0.16 | +62.06%(+$0.26) | |
| Q4 2025 | $0.01 | -$0.20 | -1974.41%(-$0.21) | |
| Q3 2025 | -$0.33 | -$0.30 | +9.09%(+$0.03) | |
| Q2 2025 | -$0.36 | -$0.48 | -34.58%(-$0.12) |
TARS Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.40
4.40
4.40
4.40
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TARSTarsus Pharmaceuticals, Inc. Common Stock | D | A | B | $71.76 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Tarsus Pharmaceuticals, Inc. Common Stock
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company developing first-in-class therapeutics for eye care. Its lead product, XDEMVY, is an investigational eye drop for treating Demodex blepharitis, with additional candidates in development for ocular rosacea and other ophthalmic conditions.